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S U M M A R Y
Cryptococcus laurentii is an extremely rare human pathogen. We report a case of primary cutaneous
cryptococcosis caused by Cryptococcus laurentii in an immunocompetent patient, an 8-year-old child
with a solitary lesion on the forearm. It was impossible to determine the source of infection and no
predisposing factors were found. Oral treatment with ﬂuconazole was totally successful. A review of the
literature showed only three cases of cutaneous infection by Cryptococcus laurentii. All of the cases
occurred in immunocompromised patients. To the best of our knowledge, this is the ﬁrst case of
Cryptococcus laurentii in an immunocompetent host.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Cryptococcus laurentii is an extremely rare human pathogen.
This fungus was previously considered saprophytic and non-
pathogenic to humans, but it has been isolated as the etiologic
agent of infections such as skin infection, keratitis, endophthalmi-
tis, lung abscess, peritonitis, meningitis, and fungemia. Only three
case reports of cutaneous cryptococcosis due to C. laurentii have
been published.1–3 Our case is the ﬁrst reported primary cutaneous
cryptococcosis in an immunocompetent host.
2. Case report
An 8-year-old girl presented with an 8-week history of an
asymptomatic hypo-pigmented macule on the right forearm. The
mother reported that the lesion had grown progressively over the
last 4 weeks. Prior to the onset of the lesion, the patient had been
healthy and her previous medical history was not relevant. The* Corresponding author. Tel.: +34 686731837.
E-mail address: alejandromolinaleyva@gmail.com (A. Molina-Leyva).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.04.017child was originally from Mongolia and had been adopted 4 years
ago. Recent contact with animals was not reported by the parents.
On physical examination, a scaly 3.5  2.8 cm ivory macule with
irregular borders was observed. The lesion showed a raised, more
desquamative erythematous area at one edge (Figure 1).
2.1. Diagnosis
Scrapings of the scale were obtained. Ciclopirox olamine
cream twice daily was initiated. At the ﬁrst follow-up visit 15
days later, the lesion remained stable. C. laurentii was conﬁrmed
by isolation of shiny light-yellow colonies on Sabouraud agar at
37 8C 48 h later. Biochemical identiﬁcation of the culture was
made using an automated API-ID32C1 (bioMe´rieux) by noting
the utilization of lactose and melibiose. A negative caffeic acid
test and absence of KNO3 utilization reliably differentiated this
species from Cryptococcus neoformans and Cryptococcus
albidus. Antifungal susceptibility testing showed that the
minimal inhibitory concentration of amphotericin B was 0.5 to
1 mg/ml, and that of ﬂuconazole was 3.5 mg/ml, according to the
broth microdilution method of the Clinical and Laboratory
Standards Institute guidelines.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Clinical image of primary cutaneous Cryptococcus laurentii infection.
Round-shaped 3.5  2.8 cm scaly white ivory macule with irregular borders. On the
left edge, a raised more desquamative erythematous area is observed.
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and C. laurentii was again isolated from the cultured colonies. With
these data, a diagnosis of primary cutaneous cryptococcosis was
made.
2.2. Treatment and evolution
Biochemical and hematological analyses were normal. Serology
for hepatitis A, B, and C viruses, cytomegalovirus, Epstein–Barr
virus, and HIV, were all negative. The T-helper/T-suppressor
lymphocyte ratio and a chest X-ray were also normal. At this point,
ﬂuconazole 3 mg/kg was started, in agreement with the clinic
pediatricians. After 2 weeks, the erythematous raised area became
ﬂattened and ﬂuconazole was discontinued. Four weeks later, a
culture for fungus was repeated, with a negative result, and the
whitish macule was reduced in size. Repigmentation of the lesion
was observed after 12 weeks. The patient has remained in good
health with no relapse after 6 months of follow-up.
3. Discussion
C. laurentii is the most common yeast found in tundra,
Antarctica, and prairie soils, as well as in the phyllosphere of
numerous ecosystems. The fecal matter of healthy birds has been
identiﬁed as an important repository for cryptococcal fungi. C.
laurentii is a psychrophilic organism and it grows poorly at
temperatures above 30 8C. While an optimal growth temperature
of 15 8C has been reported for this species, this yeast is
cryotolerant and can be successfully cultured in near freezing
conditions.
Cryptococcosis is an AIDS-related opportunistic infection found
in 6–13% of subjects with AIDS. Other cases have been described in
immunocompromised subjects with other diseases (e.g. underly-
ing malignancy) and in patients under immunosuppressive
therapy. Although the related species C. neoformans has been
identiﬁed as an important human pathogen, infections caused by
C. laurentii are rare. The main route of infection is inhalation of
airborne yeast and/or basidiospores. To-date, there have been only
17 case reports of infections caused by C. laurentii. These reports
include cutaneous, pulmonary, disseminated, and even ocular C.
laurentii infections, in AIDS and in HIV-negative individuals.1–4 In
our patient, immunity was normal and no risk factor was
identiﬁed. In previous published reports of cutaneous infectionscaused by C. laurentii, a visceral or disseminated disease was
present before or after skin involvement, however our patient
showed a skin-limited infection.1–3 Only one case of primary
cutaneous cryptococcosis has been described; this involved a
patient with a renal transplant and diabetes, probably caused by
repeated inoculations of drugs.3 Our patient did not report close
contact with pigeon excreta and she lived in southern Spain where
the climate is mild and a reservoir of C. laurentii is not probable.
Therefore we were unable to determine the source of the infection;
however, considering that our patient had lived in Mongolia for 4
years, transmissions from imported spores or spores remaining
viable in fomites are plausible routes of infection. Regarding the
clinical appearance, in previously published works, C. laurentii
cutaneous infections have presented as inﬂammatory, ulcerative,
or inﬁltrative lesions. We hypothesize that the clinical appearance
of this infection may be similar to dermatophytosis, in which
inﬂammatory and non-inﬂammatory forms are described depend-
ing on the immunological balance between the microorganism and
the host. According to this rationale, our case might represent a
benign non-inﬂammatory form.
As only three cases of primary cutaneous cryptococcosis caused
by C. laurentii have been reported, there is a lack of standard
treatment recommendations. The correlation between the results
of in vitro antifungal susceptibility tests and treatment outcome is
low. Therefore, treatment of cryptococcal diseases depends on the
anatomic site of involvement and the host immune status.4 The
therapeutic management is based on amphotericin B in mono-
therapy or associated with 5-ﬂucytosine. Azoles have recently
emerged as alternatives to amphotericin B in immunocompetent
patients. A report on the practice guidelines for the management of
cryptococcal infection recommends the use of azoles for non-
central nervous system cryptococcal infections, including cutane-
ous disease.5 Our patient received ﬂuconazole on the basis of
antifungal susceptibility test results. We used the lowest effective
dosage since the disease was benign and our patient was a child.
Fluconazole was discontinued when the lesion was found to be
healing gradually.
To the best of our knowledge, this is the ﬁrst report of skin-
limited cryptococcosis in an immunocompetent patient. In our
case, we observed non-inﬂammatory clinical lesions similar to
dermatophyte infections. The reporting of such patients might
further expand the existing spectrum of the clinical manifestations
of this disease. Whether the clinical appearance depends on
immunological status or not, is a question warranting further
research and the collection of more cases of this extremely unusual
entity.
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